Stock Analysis

Eton Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

Source: Shutterstock

Eton Pharmaceuticals (NASDAQ:ETON) Full Year 2022 Results

Key Financial Results

  • Revenue: US$21.3m (down 2.7% from FY 2021).
  • Net loss: US$9.02m (loss widened by 361% from FY 2021).
  • US$0.36 loss per share (further deteriorated from US$0.078 loss in FY 2021).
NasdaqGM:ETON Earnings and Revenue History March 18th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eton Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) exceeded analyst estimates by 5.3%.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Eton Pharmaceuticals that you should be aware of.

What are the risks and opportunities for Eton Pharmaceuticals?

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.

View Full Analysis


  • Trading at 39.3% below our estimate of its fair value

  • Earnings are forecast to grow 91.49% per year


  • Shareholders have been diluted in the past year

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
Eton Pharmaceuticals

ValuationFinancial HealthInsider TradingManagement Team